ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program ImmunoCellular Therapeutics, Ltd. announced it has entered into a sponsored research agreement with Dr. Cassian Yee at the University of Texas MD Anderson Cancer Center. The ultimate goal of this work is to enable a clinical program based on hematopoietic stem cells that are isolated from the patient, engineered in the lab and then returned to the patient to create a population of antigen-specific killer T cells that target and kill the tumor. [ImmunoCellular Therapeutics, Ltd.] Press Release Enterome and Gustave Roussy Enter into a Microbiome-Based Collaboration to Develop Novel Immunotherapy Solutions to Treat Cancer Enterome Bioscience SA announced that it has entered into a collaborative development agreement with Gustave Roussy. They aim to develop of a new generation of drugs and non-invasive monitoring tools of the gut microbiome in immuno-oncology. [Enterome Bioscience SA] Press Release Cellular Dynamics Announces Collaboration with Roche Cellular Dynamics International, Inc. announced an agreement with Roche to supply CDI’s induced pluripotent stem cell-derived iCell products to contribute to the identification of novel drug candidates at the early stages of drug discovery. [Cellular Dynamics International, Inc.] Press Release Moffitt Cancer Center’s Physical Sciences – Oncology Center Receives $10.4 Million Grant to Study the Intersection of Evolution and Cancer Therapy The Integrated Mathematical Oncology (IMO) Department integrates their skills with cancer biologists and oncologists in teams to use mathematical models to better understand cancer progression and treatment. This team driven science has led to pioneering work that has recently been acknowledged through a $10.4 million award from the National Cancer Institute, designating Moffitt as one of the five Physical Science – Oncology Centers. [Moffitt Cancer Center (Newswire Inc.)] Press Release Derma Sciences Announces Results of Futility Analyses for Phase III Clinical Trials of Aclerastide in Diabetic Foot Ulcer Healing Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, announced the termination of its Phase III clinical trials with aclerastide for diabetic foot ulcer healing. [Derma Sciences, Inc.] Press Release Will HER-2 Targeted Treatment Improve the Efficacy of Chemotherapy for Early HER-2 Positive Gastric Cancer? EORTC trial 1203 –Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer, is open for recruitment for patients with early, HER-2 positive gastric cancer. [European Organisation for Research and Treatment of Cancer (EORTC)] Press Release Celyad Successfully Completes 30-Day Safety Follow-Up of First Patient Cohort in NKG2D CAR T-Cell Phase I Trial Celyad announced the completion of the 30-day safety follow-up of the final patient enrolled in the first cohort of the company’s Phase I clinical trial evaluating the safety and feasibility of its NKG2D CAR T-Cell therapy in cancer patients suffering from acute myeloid leukemia or multiple myeloma. [Celyad] Press Release Regeneus Ltd. Patent Granted for Allogeneic Stem Cell Technology Platform Regeneus announced that the Australian Patent Office has granted a key patent covering the use of the company’s allogeneic “off-the-shelf” stem cell technology for the treatment of osteoarthritis and other inflammatory conditions for human and animal applications. [Regeneus Ltd. (ABN Newswire)] Press Release Cellular Biomedicine Group Opens New GMP Facility in Beijing Cellular Biomedicine Group Inc. announced the opening of its new state-of-the-art facility in Beijing. Eight hundred square meters of the 1,400 square meter site has been equipped with four independent production lines to support clinical batch production and commercial scale manufacturing. [Cellular Biomedicine Group Inc.] Press Release |